Mod-GRF 1-29 Purity & Testing — Research Reference
Mod-GRF 1-29, recognized as a modified GRF(1-29) growth hormone-releasing hormone (GHRH) analog, stands as a pivotal peptide in the realm of growth hormone research, often identified by its alias CJC-1295 without DAC. Ensuring its purity and comprehensive characterization is paramount for any scientific investigation, as these factors directly impact the reproducibility, validity, and interpretability of experimental results. This reference serves as a foundational resource for researchers seeking to understand the rigorous standards and methodologies applied to assess the quality of Mod-GRF 1-29 for laboratory use.
The extensive body of work surrounding Mod-GRF 1-29 underscores its significance, with numerous publications indexed on PubMed detailing its mechanism and research applications, alongside several registered studies on ClinicalTrials.gov that further explore its investigational utility. For any research involving this class of GHRH analog, a thorough understanding of its chemical properties, purity profile, and appropriate testing protocols is indispensable to prevent confounding variables and to ensure that observed outcomes are genuinely attributable to the intended peptide.
The Critical Role of Peptide Purity in Research Integrity
In the rigorous landscape of cellular aging research, where subtle molecular shifts can dictate profound phenotypic outcomes, the unwavering purity of research peptides stands as a foundational pillar for scientific integrity. Contaminants, even at trace levels, can introduce significant confounding variables, leading to misinterpretation of data, irreproducible results, and ultimately, a substantial drain on resources and research timelines. When investigating the intricate mechanisms of growth hormone secretagogues or their analogs, such as Mod-GRF 1-29, the presence of impurities – whether they are residual solvents, synthesis byproducts, truncated peptide sequences, or even microbial contaminants – can directly interfere with receptor binding kinetics, alter downstream signaling cascades, or elicit non-specific cellular responses entirely unrelated to the peptide of interest. This makes stringent purity assessment not merely a quality control measure, but an indispensable prerequisite for generating credible and impactful scientific knowledge.
The impact of impure research materials extends beyond the immediate experimental readout, permeating the entire scientific ecosystem. Researchers rely on the fidelity of published work, and studies conducted with inadequately characterized peptides can propagate erroneous conclusions, hindering the accurate progression of understanding in areas as critical as cellular senescence, telomere dynamics, or metabolic regulation during aging. For instance, a minor impurity might act as a partial agonist or antagonist at a receptor site, subtly altering the dose-response curve of the intended peptide, or it could activate an entirely different pathway, incorrectly attributing an observed effect to Mod-GRF 1-29 itself. Such artifacts compromise the very essence of hypothesis testing and mechanistic elucidation, making it impossible to confidently delineate the true biological actions of the peptide. Therefore, meticulous attention to peptide purity is paramount for ensuring the validity and reproducibility of scientific discoveries, fostering trust within the research community, and enabling genuine advancements in the complex field of aging biology.
Moreover, the increasingly complex nature of peptide synthesis and modification necessitates advanced analytical oversight. Modern synthetic methodologies, while highly efficient, are not infallible and can yield a spectrum of related impurities. These impurities often share similar physiochemical properties with the target peptide, making their separation and detection challenging. The structural complexity of Mod-GRF 1-29, a modified GHRH analog, means that even minor variations in its amino acid sequence or post-translational modifications could drastically alter its pharmacological profile. Without a robust purity profile, researchers cannot confidently attribute observed cellular or physiological changes to the intended peptide, thereby undermining the validity of their conclusions. This critical need for verified purity underscores why reputable suppliers prioritize comprehensive analytical testing, providing researchers with the assurance required to embark on their studies with confidence in their starting materials. Understanding the fundamental role of what are research peptides is the first step towards appreciating the depth of quality control required.
Mod-GRF 1-29: Structural Characteristics and Research Mechanism
Mod-GRF 1-29, an acronym for Modified Growth Hormone Releasing Factor (1-29), stands as a significant GHRH analog in the realm of growth hormone research. This synthetic peptide is a truncated and modified version of the naturally occurring Growth Hormone-Releasing Hormone (GHRH), specifically encompassing the first 29 amino acids of the parent molecule. The strategic modifications within its sequence are designed to enhance its stability and bioavailability in research models, providing a more robust and sustained engagement with its target receptor. Unlike its natural counterpart which has a relatively short half-life due to rapid enzymatic degradation, Mod-GRF 1-29 is engineered to resist dipeptidyl peptidase-IV (DPP-IV) cleavage, a primary mechanism of GHRH inactivation. This structural enhancement is achieved through specific amino acid substitutions at positions 2 and 8, significantly prolonging its active presence in systemic circulation and thereby extending its influence on the somatotropic axis within research contexts.
The fundamental research mechanism of Mod-GRF 1-29 revolves around its potent agonistic activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor primarily expressed on somatotroph cells in the anterior pituitary gland. Upon binding to the GHRH-R, Mod-GRF 1-29 initiates a cascade of intracellular events. This binding activates adenylyl cyclase via Gs proteins, leading to an increase in intracellular cyclic AMP (cAMP) levels. Elevated cAMP then triggers protein kinase A (PKA), which phosphorylates various downstream targets, ultimately stimulating both the synthesis and pulsatile release of growth hormone (GH) from the somatotrophs. This mechanism mimics the natural physiological process but with an enhanced pharmacokinetic profile, allowing researchers to study the effects of sustained, yet physiological, GH stimulation in various biological models. The precise control over GH secretion makes Mod-GRF 1-29 a valuable tool for investigating GH’s role in metabolism, body composition, tissue repair, and, critically for our field, its potential influences on the aging process and age-related decline in GH output.
Functional Implications in Research
The prolonged half-life and potent GHRH-R agonism of Mod-GRF 1-29 afford researchers a unique avenue to explore the implications of augmented GH secretion. In various preclinical studies, Mod-GRF 1-29 has been instrumental in characterizing the somatotropic axis and its contributions to diverse physiological processes. Research has demonstrated its capacity to elicit a dose-dependent increase in GH levels, subsequently influencing IGF-1 production, which serves as a major mediator of GH’s anabolic and metabolic effects. This sustained elevation of GH and IGF-1 has been investigated across numerous models pertaining to muscle maintenance, bone density, and metabolic homeostasis. For cellular aging researchers, understanding how Mod-GRF 1-29 modulates these pathways is crucial for dissecting the intricate interplay between growth factors, hormones, and cellular longevity, particularly in the context of age-related sarcopenia, osteopenia, and metabolic dysregulation.
The robust scientific literature supports the utility of Mod-GRF 1-29 as a research tool. It is categorized as a GHRH analog with a well-established mechanism, studied in growth-hormone research. The compound has been extensively referenced, with numerous publications indexed in PubMed, providing a rich historical context for its application and observed effects in various research settings. Furthermore, its research relevance is underscored by several registered studies on ClinicalTrials.gov, indicating its progression into more advanced translational research stages, albeit strictly within the confines of investigative protocols. Its alias, “CJC-1295 without DAC,” highlights its structural similarity to other GHRH analogs, specifically differentiating it from versions containing a Drug Affinity Complex (DAC) which further extends its half-life by binding to albumin. This distinction is crucial for researchers needing to select the appropriate GHRH analog for their specific experimental design, based on the desired duration and pattern of GH stimulation. Detailed insights into its action can be found on our dedicated page: Mod-GRF 1-29 Mechanism of Action.
Advanced Analytical Techniques for Mod-GRF 1-29 Purity Assessment
Ensuring the high purity of Mod-GRF 1-29 is paramount for reliable research outcomes, necessitating the deployment of sophisticated analytical techniques capable of detecting and quantifying even trace impurities. High-Performance Liquid Chromatography (HPLC) is the cornerstone of peptide purity assessment. Specifically, reversed-phase HPLC (RP-HPLC) is widely utilized due to its excellent separation capabilities for peptides based on their hydrophobicity. By optimizing the stationary phase, mobile phase composition, and gradient elution profiles, RP-HPLC can effectively resolve the target peptide from synthesis byproducts, truncated sequences, oxidized forms, and other related impurities. The percentage purity is typically determined by integrating the area under the main peptide peak relative to the total area of all detected peaks. This method provides a quantitative measure of purity, essential for qualifying research batches.
Beyond quantitative purity, the unequivocal identification and characterization of Mod-GRF 1-29 and any detected impurities are crucial. Liquid Chromatography-Mass Spectrometry (LC-MS) serves as an indispensable tool in this regard, combining the separation power of LC with the molecular mass analysis capabilities of MS. This hyphenated technique allows researchers to determine the exact molecular weight of the intact peptide and its fragments, providing confirmation of the primary sequence and any post-translational modifications or degradative changes. LC-MS/MS (tandem MS) further enhances characterization by fragmenting precursor ions, yielding rich structural information that can be used to identify specific amino acid substitutions, deletions, or other structural aberrations. This level of detail is critical for understanding the nature of impurities and confirming that the synthesized peptide precisely matches the desired Mod-GRF 1-29 sequence, ensuring researchers are working with the correct compound.
Complementary Spectroscopic and Elemental Analysis
Nuclear Magnetic Resonance (NMR) spectroscopy, particularly 1H and 13C NMR, provides atom-level structural information, confirming the identity and conformation of the peptide. While less commonly used for routine purity checks due to its sensitivity and sample requirements, NMR is invaluable for definitive structural elucidation, especially for novel peptides or when ambiguous results arise from other methods. For Mod-GRF 1-29, NMR can confirm the correct connectivity and stereochemistry, providing a molecular fingerprint of the pure compound. Additionally, amino acid analysis (AAA) quantitatively determines the amino acid composition of the hydrolyzed peptide, serving as an independent verification of the peptide’s elemental building blocks and confirming the correct molar ratios of each amino acid, indirectly supporting the expected sequence.
To ensure comprehensive quality control, additional analytical methods address specific types of contaminants. Residual solvent analysis, often performed using Gas Chromatography (GC) or Headspace GC-MS, identifies and quantifies any remaining solvents from the synthesis and purification process. These solvents, even at low concentrations, can impact cellular viability or interfere with enzymatic reactions in sensitive research models. Karl Fischer titration is employed to determine water content, which is critical for peptides prone to hydrolysis or for accurate gravimetric dispensing. Taken together, these advanced analytical techniques form a robust framework for assessing the purity, identity, and overall quality of Mod-GRF 1-29, empowering researchers with confidence in their experimental materials. The full scope of our quality assurance is detailed on our quality testing page.
Comprehensive Identity Verification and Characterization Protocols
Beyond mere purity assessment, a comprehensive identity verification protocol is indispensable for research-grade Mod-GRF 1-29. This protocol ensures that the synthesized peptide unequivocally matches the intended chemical structure and biological activity profile for Mod-GRF 1-29, a modified GRF(1-29) GHRH analog. The process begins with confirming the primary sequence, which is the precise order of amino acids within the peptide chain. Edman degradation, though classical, can still be employed for N-terminal sequencing, while modern mass spectrometry techniques, particularly LC-MS/MS, provide a more rapid and comprehensive method for de novo sequencing or sequence confirmation. Fragment ions generated during MS/MS analysis can be matched against theoretical fragmentation patterns of Mod-GRF 1-29, offering highly conclusive evidence of its amino acid sequence. This step is critical because even a single amino acid substitution or deletion can profoundly alter the peptide’s folding, stability, and receptor binding affinity, rendering it unsuitable for specific research applications.
Molecular weight determination is another cornerstone of identity verification. High-resolution mass spectrometry (HRMS) offers exceptional accuracy in measuring the molecular mass of the intact peptide, providing a precise value that can be compared to the theoretical molecular weight of Mod-GRF 1-29. Deviations from the theoretical mass can indicate the presence of impurities, uncompleted synthesis products, or unintended modifications. For instance, an observed mass shift could suggest an oxidation event, the incorporation of an incorrect amino acid, or the presence of a non-peptide adduct. Combined with accurate mass measurements, the isotopic distribution pattern observed in the mass spectrum further confirms the elemental composition. This level of scrutiny ensures that the researcher is indeed utilizing the specified GHRH analog, CJC-1295 without DAC, which is crucial for consistency across studies and for drawing accurate conclusions about its mechanism.
Biochemical and Functional Characterization
To complement the structural identity verification, biochemical and functional characterization are often employed, particularly for ensuring the peptide’s bioactivity in relevant research contexts. While direct biological activity assays are not always part of routine quality control for every batch, they are fundamental for initial characterization and validation of the synthesis process. For Mod-GRF 1-29, this could involve in vitro assays to assess its ability to stimulate cAMP production in GHRH-R expressing cells or to induce GH release from primary pituitary cell cultures. Although not used for human applications, these research assays confirm that the peptide is not only structurally correct but also functionally active at its target receptor, thereby possessing the expected signaling properties. Furthermore, characterization might extend to Circular Dichroism (CD) spectroscopy to assess the secondary structure of the peptide, confirming its conformational integrity, which is directly linked to its biological activity and stability.
Finally, a multi-modal approach to identity verification is essential to mitigate the risk of misidentification or mischaracterization. The combination of chromatographic, spectroscopic, and mass spectrometric data creates a comprehensive profile that serves as a unique fingerprint for Mod-GRF 1-29. This holistic approach ensures that every aspect of the peptide’s identity, from its primary sequence and molecular weight to its potential post-translational modifications, is rigorously confirmed. For researchers working with Mod-GRF 1-29 in complex cellular aging models, this thorough characterization is not just a best practice but a critical requirement for maintaining the scientific rigor and reproducibility of their experiments. The table below summarizes key techniques employed for comprehensive identity verification:
| Technique | Primary Purpose | Information Provided |
|---|---|---|
| LC-MS/MS | Sequence Confirmation & Molecular Weight | Primary amino acid sequence, accurate molecular mass, fragmentation patterns |
| RP-HPLC | Purity & Chromatographic Profile | Relative abundance of target peptide vs. impurities, retention time |
| Amino Acid Analysis (AAA) | Compositional Verification | Quantitative amino acid ratios, confirming stoichiometry |
| NMR Spectroscopy | Structural Elucidation | Atom-level structural confirmation, chemical shifts, connectivity |
| Circular Dichroism (CD) | Secondary Structure Assessment | Confirmation of alpha-helix/beta-sheet content, conformational integrity |
Essential Safety Parameter Testing: Endotoxins and Sterility for Research
For any research involving peptides, particularly those intended for in vivo studies or cell culture experiments, assessing safety parameters such such as endotoxin levels and sterility is critically important. Endotoxins, also known as lipopolysaccharides (LPS), are potent pyrogenic components of the outer membrane of Gram-negative bacteria. Even at picogram concentrations, endotoxins can elicit robust inflammatory responses in mammalian cells and organisms, including fever, cytokine release, and immune cell activation. In the context of cellular aging research, an endotoxin contamination could profoundly confound experimental results, falsely attributing inflammatory or stress responses to Mod-GRF 1-29 when they are, in fact, artifacts of bacterial contamination. This could lead to erroneous conclusions about the peptide’s role in modulating cellular senescence pathways, oxidative stress, or immune responses, thereby invalidating years of painstaking research. Therefore, rigorous testing for endotoxins using methods like the Limulus Amebocyte Lysate (LAL) assay is an absolute necessity to ensure the biological inertness of the peptide stock concerning inflammatory stimuli.
The LAL assay is the gold standard for endotoxin detection and quantification. It leverages the coagulation cascade found in the horseshoe crab’s (Limulus polyphemus) amebocytes, which is exquisitely sensitive to LPS. Various LAL assay formats exist, including gel clot, turbidimetric, and chromogenic assays, each offering different levels of sensitivity and quantification capabilities. For research-grade Mod-GRF 1-29, the endotoxin limit is typically set to extremely low levels, often less than 0.01 EU/µg (Endotoxin Units per microgram of peptide) or 0.005 EU/mL for solutions, to ensure minimal biological interference. Adherence to these stringent limits is crucial, especially for studies involving sensitive primary cell cultures, immune-competent animal models, or investigations into the subtle molecular changes associated with aging. Without careful control of endotoxin levels, it becomes impossible to differentiate between the true effects of Mod-GRF 1-29 as a GHRH analog and the non-specific, pro-inflammatory effects of contaminants.
Sterility Assurance for In Vitro and In Vivo Applications
Parallel to endotoxin testing, ensuring the sterility of research peptides is equally vital, particularly when they are to be introduced into sterile cell culture environments or living organisms. Sterility refers to the complete absence of viable microorganisms, including bacteria, fungi, and their spores. Microbial contamination, even at low levels, can rapidly proliferate in nutrient-rich cell culture media, altering pH, depleting essential nutrients, producing toxins, and ultimately leading to cell death or significant changes in cellular physiology. For in vivo studies, non-sterile peptide solutions can introduce infections, leading to illness or death of research animals, thereby compromising ethical standards and experimental validity. Therefore, sterility testing is performed under strictly controlled aseptic conditions to detect the presence of any microbial growth.
Sterility testing typically involves inoculating aliquots of the reconstituted peptide solution into various growth media designed to support the proliferation of different types of microorganisms (e.g., thioglycollate medium for anaerobic and aerobic bacteria, and soybean-casein digest medium for fungi and aerobic bacteria). These inoculated media are then incubated for a specified period (e.g., 14 days) at appropriate temperatures, and regularly observed for signs of microbial growth (turbidity). The absence of growth across all tested media confirms the sterility of the peptide preparation. For research-grade Mod-GRF 1-29, the manufacturing process incorporates strict aseptic techniques and, where appropriate, terminal sterilization methods like sterile filtration (e.g., through a 0.22 µm filter) for solutions, ensuring the final lyophilized product or reconstituted stock meets stringent sterility requirements. This dual focus on endotoxin reduction and sterility guarantees that the research material is free from biological contaminants that could skew results or harm research models, enabling researchers to focus solely on the specific effects of the peptide.
Optimal Storage, Handling, and Stability for Mod-GRF 1-29 Research Stock
The integrity and biological activity of Mod-GRF 1-29 as a research peptide are highly dependent on appropriate storage and handling practices. Peptides are inherently delicate molecules, susceptible to degradation through various pathways including hydrolysis, oxidation, and enzymatic cleavage. To preserve its structural and functional fidelity, Mod-GRF 1-29 is typically supplied in its lyophilized (freeze-dried) form. Lyophilization removes water, a primary medium for chemical reactions, thereby significantly enhancing the peptide’s long-term stability. The optimal storage condition for lyophilized Mod-GRF 1-29 is typically at -20°C or colder, ideally in a frost-free freezer that minimizes temperature fluctuations. It should be stored in tightly sealed containers, often amber vials, to protect it from light and moisture ingress. Exposure to elevated temperatures, humidity, or direct light can accelerate degradation, leading to a loss of purity and potency, which can profoundly impact experimental reproducibility and interpretation. Adherence to these conditions is paramount until the moment of reconstitution for research use.
Reconstitution is a critical step that requires meticulous attention to detail. The choice of solvent and method significantly influences the peptide’s stability and solubility. For Mod-GRF 1-29, reconstitution is typically performed using sterile bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol) for maintaining sterility for multiple withdrawals, or sterile distilled water (for immediate use or if benzyl alcohol might interfere with specific assays). The peptide should be allowed to reach room temperature before opening the vial to prevent condensation, which can introduce moisture. The solvent should be added slowly to the vial wall, not directly onto the peptide powder, to avoid foaming. Gentle swirling, rather than vigorous shaking, is recommended to ensure complete dissolution without causing peptide denaturation. Once reconstituted, the peptide solution enters a more labile state, and its stability window significantly shortens, necessitating specific storage conditions to maintain its research efficacy.
Post-Reconstitution Storage and Handling
After reconstitution, Mod-GRF 1-29 solutions should be stored refrigerated at 2-8°C. While some peptides can tolerate limited freeze-thaw cycles, repeated freezing and thawing are generally discouraged as it can lead to aggregation and degradation, particularly for larger or more complex peptides. If long-term storage of reconstituted Mod-GRF 1-29 is required, it is advisable to aliquot the solution into smaller, single-use vials to minimize the number of freeze-thaw cycles for the entire stock and reduce potential contamination from repeated access. These aliquots can then be stored at -20°C or colder. The use of sterile techniques throughout the reconstitution and aliquoting process is non-negotiable to prevent microbial contamination, which can rapidly degrade the peptide and compromise experimental integrity, especially for in vitro studies.
The duration for which a reconstituted peptide solution remains stable and biologically active varies depending on the specific peptide, its concentration, the solvent used, and storage conditions. While general guidelines exist, it is prudent for researchers to establish their own stability profiles if long-term storage of reconstituted solutions is critical for their experimental design. For Mod-GRF 1-29, reconstituted solutions typically maintain acceptable stability for several weeks when stored at 2-8°C, and for several months when stored at -20°C in aliquots. However, any visual signs of turbidity, precipitation, or discoloration indicate potential degradation and warrant discarding the stock. Careful documentation of reconstitution dates, concentrations, and storage conditions is essential for maintaining experimental consistency and ensuring the reliability of research data. For more detailed protocols and best practices, researchers are encouraged to consult our dedicated resource on Mod-GRF 1-29 Storage and Handling.
Interpreting Certificates of Analysis (CoAs) for Mod-GRF 1-29
A Certificate of Analysis (CoA) serves as a critical document, acting as a testament to the quality, identity, and purity of a research peptide like Mod-GRF 1-29. For cellular aging researchers, understanding how to thoroughly interpret a CoA is paramount for ensuring that the purchased peptide meets the rigorous standards required for their specific experimental designs. A comprehensive CoA provides detailed analytical data obtained through various testing methodologies, offering transparency and accountability from the peptide supplier. Key sections typically include the peptide’s name (Mod-GRF 1-29), its CAS number, molecular formula, molecular weight, and amino acid sequence, allowing for immediate confirmation of the compound’s identity. This foundational information is crucial for cross-referencing with existing literature and ensuring the correct material has been received.
Beyond basic identification, the CoA details the results of critical purity assessments. The most prominent of these is typically the HPLC Purity, expressed as a percentage. For research-grade Mod-GRF 1-29, this percentage should consistently be at 98% or higher, with some high-quality vendors offering 99%+. This figure indicates the proportion of the target peptide relative to all other detectable components in the sample. A lower purity percentage suggests a higher presence of impurities, which, as discussed, can introduce significant confounding variables into sensitive cellular and animal models. Researchers should also examine the accompanying chromatogram (often included or available upon request) to visually inspect the presence and size of any impurity peaks. Additionally, the CoA will typically report the results of Mass Spectrometry (MS) analysis, providing the observed molecular mass of the peptide. This data should closely match
Frequently Asked Questions
What is Mod-GRF 1-29?
Mod-GRF 1-29 is a synthetic GHRH analog, specifically a modified fragment of Growth Hormone-Releasing Factor (GRF(1-29)), extensively studied in growth hormone research to investigate GHRH receptor interactions and downstream effects. It is also known as CJC-1295 without DAC.
Why is peptide purity crucial for research using Mod-GRF 1-29?
High peptide purity is critical to ensure that observed experimental outcomes are directly attributable to Mod-GRF 1-29, minimizing the influence of impurities that could introduce confounding variables, compromise reproducibility, and lead to inaccurate or misleading research conclusions.
What analytical methods are typically employed to determine Mod-GRF 1-29 purity?
Primary analytical methods for Mod-GRF 1-29 purity assessment include High-Performance Liquid Chromatography (HPLC) for quantification of the main peptide component, and Mass Spectrometry (MS) for precise molecular weight verification and detection of related substances or adducts.
What level of purity is generally considered research-grade for Mod-GRF 1-29?
For rigorous research, Mod-GRF 1-29 typically requires a purity of 95% or higher, with 98% or greater often preferred. Higher purity minimizes the presence of truncated sequences, oxidation products, or other synthetic byproducts that could interfere with experimental results.
What are bacterial endotoxins, and why are they relevant for Mod-GRF 1-29 research?
Bacterial endotoxins are lipopolysaccharides (LPS) from Gram-negative bacteria that can induce inflammatory, pyrogenic, and immunomodulatory responses, particularly in *in vivo* research models. Testing for and minimizing endotoxin levels is essential to prevent experimental artifacts unrelated to Mod-GRF 1-29’s intended biological activity.
How should Mod-GRF 1-29 be stored to maintain its integrity for research purposes?
Lyophilized Mod-GRF 1-29 should be stored long-term at -20°C or colder, ideally in a desiccated environment and protected from light. Reconstituted solutions should be handled carefully, used promptly, or stored refrigerated/frozen for short durations, strictly avoiding repeated freeze-thaw cycles.
What information should a comprehensive Certificate of Analysis (CoA) for Mod-GRF 1-29 include?
A comprehensive CoA for Mod-GRF 1-29 should detail key analytical data such as peptide purity (e.g., RP-HPLC chromatogram and percentage), molecular weight (MS data), amino acid composition (AAA), water content, counter-ion identity, and bacterial endotoxin levels, all specific to the research batch.
How can researchers verify the identity of their Mod-GRF 1-29 research material?
Identity verification for Mod-GRF 1-29 is primarily achieved by combining robust analytical data, notably through the confirmation of the peptide’s expected molecular mass via Mass Spectrometry and by comparing its High-Performance Liquid Chromatography (HPLC) retention time against well-characterized standards or established literature values.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.